The fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts. Since the superiority of 68Ga-PSMA-11 PET in detecting recurrent PCA is well established, the aim of our study was to assess its effect on management and outcome in all patients imaged during the first year after its introduction into clinical routine.
Of 327 patients imaged, 223 were referred for recurrent PCA and gave written informed consent for further analysis of their data for this retrospective consecutive cohort analysis. Twenty patients were lost to further follow-up. The rate of detection of recurrence by 68Ga-PSMA-11 PET was based on the clinical reports. Management before the availability of PET diagnostic information was assessed according to guidelines (therapy option without 68Ga-PSMA-11 PET). In the 203 patients with follow-up 6 months after 68Ga-PSMA-11 PET, the therapies effectively implemented as well as follow-up PSA levels were evaluated, with a PSA value of <0.2 ng/ml representing a complete response and a decrease in PSA value of at least 50% from baseline representing a partial response.
68Ga-PSMA-11 PET was positive and identified recurrence in 166 of the 223 patients (74%), with a detection rate of 50% for recurrent disease at low PSA values of <0.5 ng/ml. 68Ga-PSMA-11 PET led to a change in management in 122 of the 203 patients (60%). A substantial increase in the use of metastasis-targeted treatment and a reduction in the use of systemic treatment were observed, with 59 of the 203 patients (29%) undergoing targeted radiotherapy (RTXa) only, and 20 patients (10%) undergoing RTXa with hormonal therapy as the two most frequently selected therapy options. The proportion of patients in whom systemic therapy was selected decreased from 60% (133 of 223 patients) to 34% (70 of 203 patients) on the basis of the information provided by the 68Ga-PSMA-11 PET scan. PSMA PET-directed metastasis-targeted treatment led to a complete response after 6 months in 45% of patients.
The high rate of recurrence detection by PSMA PET was confirmed and PSMA PET led to a change in management in 60% of patients. Focal therapy for PSMA-positive lesions is a promising approach with complete responses in 45% of patients.
European journal of nuclear medicine and molecular imaging. 2018 Nov 28 [Epub ahead of print]
Julian Müller, Daniela A Ferraro, Urs J Muehlematter, Helena I Garcia Schüler, Sarah Kedzia, Daniel Eberli, Matthias Guckenberger, Stephanie G C Kroeze, Tullio Sulser, Daniel M Schmid, Aurelius Omlin, Alexander Müller, Thomas Zilli, Hubert John, Helmut Kranzbuehler, Philipp A Kaufmann, Gustav K von Schulthess, Irene A Burger
Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland., Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland., Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland., Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Department of Urology, Spital Limmattal, Schlieren, Switzerland., Department of Radiation Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland., Department of Radiation Oncology, Stadtspital Triemli, Zürich, Switzerland., Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland. .